• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Allergan

Allergan

Allergan PLC AGN

Last Price$243.94Day Change (%)0.21%
Open Price$242.49Day Change ($)0.51
Day Range242.49–246.5052-Week Range195.50–322.68

As of Fri 9/23/2016 6:18:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Pharmaceuticals Manufacturers (Global) - Industry Report 2016: Individual Analysis of the Top 90 Companies Including Pfizer Inc, Novo Nordisk A/S & Allergan Inc - Research and Markets

    Pharmaceuticals Manufacturers (Global) - Industry Report 2016: Individual Analysis of the Top 90 Companies Including Pfizer Inc, Novo Nordisk A/S & Allergan Inc - Research and Markets

  2. UPDATE: Allergan is paying a stunning 500% premium to buy a clinical-stage biotech

    UPDATE: Allergan is paying a stunning 500% premium to buy a clinical-stage biotech

  3. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding the Fairness of the Sale of Vitae Pharmaceuticals, Inc. to Allergan plc for $21.00 Per Share

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding the Fairness of the Sale of Vitae Pharmaceuticals, Inc. to Allergan plc for $21.00 Per Share

  4. Ambry Genetics’ CEO Aaron Elliott Receives OC Business Journal’s ‘Innovator of the Year’ Award

    Ambry Genetics’ CEO Aaron Elliott Receives OC Business Journal’s ‘Innovator of the Year’ Award

  5. Global Spinal Cord Injury Clinical Trials Review, H2, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Pfizer, Allergan , Stem Cell Sciences - Research and Markets

    Global Spinal Cord Injury Clinical Trials Review, H2, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Pfizer, Allergan , Stem Cell Sciences - Research and Markets

  6. Seasonal Affective Disorder (SAD) Global Clinical Trials Review, H2, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: GlaxoSmithKline, Allergan , SFBC - Research and Markets

    Seasonal Affective Disorder (SAD) Global Clinical Trials Review, H2, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: GlaxoSmithKline, Allergan , SFBC - Research and Markets

  7. UPDATE: Yes, you are paying a lot more for prescription drugs (and not just the EpiPen)

    UPDATE: Yes, you are paying a lot more for prescription drugs (and not just the EpiPen)

  8. UPDATE: Yes, you are paying a lot more for prescription drugs (and not just the EpiPen)

    UPDATE: Yes, you are paying a lot more for prescription drugs (and not just the EpiPen)

  9. Yes, you are paying more a lot more for prescription drugs (and not just the EpiPen)

    Yes, you are paying more a lot more for prescription drugs (and not just the EpiPen)

  10. Novel Drugs and Devices to Lower Intraocular Pressure, 2016 - 2026 - Research and Markets

    Novel Drugs and Devices to Lower Intraocular Pressure, 2016 - 2026 - Research and Markets

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.